Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Genetics Laboratory Receives California Approval to Offer Testing

NEW YORK (GenomeWeb) – Oncology diagnostics firm Cancer Genetics today announced that its CLIA-certified, CAP-accredited laboratory has received the California Clinical Laboratory License, which will allow the company to perform its oncology testing services on patient samples from the state of California.

The Rutherford, NJ-based firm said in a statement that it believes its proprietary tests for non-Hodgkin's lymphoma (NHL) and leukemia will be of particular benefit to the state, where more than 6,800 new patients are diagnosed with NHL, and 4,300 patients are diagnosed with leukemia each year. 

"Approval to provide our comprehensive oncology tests and services throughout California opens up the single largest US oncology diagnostics market to CGI, and will help accelerate our commercial growth," Cancer Genetics CEO Panna Sharma said in a statement.

Cancer Genetics received CLIA and New York State approvals in May 2014 to offer its lymphoma tests and got the same approvals for its leukemia tests in February 2013.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.